Michael Bauer, born in 1963, is Professor and Chair of Anesthesiology and Intensive Care and chief executive director of the Center for Sepsis Control Care (CSCC) at University Hospital Jena, Germany. He received his M.D. from Saarland University and postgraduate training in molecular biology at Johns Hopkins University in Baltimore, USA (1993–1995). In 1997 he qualified as a professor in anesthesiology and intensive care medicine at Saarland University. After board certification in anesthesiology and intensive care, he was a visiting professor at the University of North Carolina in Charlotte (1998–1999). Dr. Bauer works on molecular mechanisms of sepsis and shock-related organ dysfunction with a focus on personalized, theranostic, and biophotonic strategies to visualize liver function.

Activities

Professor Bauer serves as member of the board of directors of the cluster of excellence “Balance of the Microverse” (EXC 2051; Project-ID 390713860) in the Jena Center for Soft Matter (JCSM), the research campus InfectoGnostics and the Leibniz Center for Photonics in Infection Research. He is vice-speaker of CRC (SFB) 1278 “Polymer-based nanoparticle libraries for targeted anti-inflammatory strategies” (PolyTarget) and chairman for Thuringia of the German Society for Anaesthesiology and Critical Care (DGAI).

Awards

Michael Bauer received a scholarship from the German National Academic Foundation and a Feodor Lynen scholarship from the Alexander von Humboldt Foundation. In 1996 he received the research award from the German Society for Anesthesiology and Intensive Care Medicine (research grant from the Fresenius Foundation) and the Manfred Specker Medal from the DGAI for mentoring. In 2015 he received the innovation award of the state of Thuringia & special award for young companies (SmartDyeLivery, GmbH) and in 2019 the Thuringian Research Award for Applied Research (RAMANBIOASSAY^TM).

Focus

The main interest of Professor Bauer's work is nanomedicine with a focus on selective targeting of parenchymal and non-parenchymal cells of the liver, as well as target identification of RNAs, proteins and metabolites of the human systemic inflammatory response to pathogens and microbiome-host interactions in intensive care patients.

Methods

• Omic profiling (transcriptomics, proteomics, metabolomics, next generation sequencing)
• Biophotonics (in vivo microscopy and multimodal imaging)
• Clinical trials